Loading...

Gefitinib enhances sensitivity of endometrial cancer cells to progestin therapy via dual-specificity phosphatase 1

In this study, we investigated if Gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, augments endometrial cancer (EC) therapy with medroxyprogesterone acetate (MPA). Combined treatment with Gefitinib plus MPA decreased the proliferation and invasiveness of the Ishikawa and RL952 EC cel...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncotarget
Main Authors: Yang, Yuan, Zhou, Jingyi, Li, Xiaoping, Zhao, Lijun, Cheng, Yuan, Lin, Yanying, Wang, Jiaqi, Wei, Lihui, Dong, Yafeng, Wang, Jianliu
Format: Artigo
Sprog:Inglês
Udgivet: Impact Journals LLC 2017
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5777777/
https://ncbi.nlm.nih.gov/pubmed/29383165
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23264
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!